Skip to main content

Table 2 Changes of the inflammatory and structural parameters between baseline and week 24

From: Resolution of synovitis and arrest of catabolic and anabolic bone changes in patients with psoriatic arthritis by IL-17A blockade with secukinumab: results from the prospective PSARTROS study

Characteristic Baseline Week 24 P value
MRI
 PSAMRIS Synovitis (median,IQR) 3 (2, 7) 2 (0, 4) 0.034*
 PSAMRIS Osteitis (median,IQR), (mean ± SD)† 0 (0, 5)†, 1.2 ± 3.1 0 (0, 0)†, 0.5 ± 1.3 0.180
 PSAMRIS Periarticular (median,IQR) (mean ± SD)† 0 (0, 1)†, 0.7 ± 1.6 0 (0, 0)†, 0 ± 0 0.059
 PSAMRIS Tenossynovitis (median,IQR) (mean ± SD)† 0 (0, 1.5)†, 1.2 ± 2.2 0 (0, 0)†, 0.7 ± 1.7 0.400
 PSAMRIS Erosions (median, IQR) 1 (0, 3) 1 (0, 4) 0.167
 PSAMRIS Proliferation (median,IQR) (mean ± SD)† 0 (0, 1)†, 1.2 ± 2.6 0 (0, 1)†, 1.2 ± 2.6 0.655
 Total PSAMRIS (median, IQR) 6 (3.5, 18) 4 (1, 13.5) 0.039*
PDUS
 OMERACT Hypertrophy (median, IQR) 5 (2, 9.5) 1 (0, 3.5) 0.009**
 OMERACT Effusion (median, IQR) (mean ± SD)† 4 (0.5, 6.5)†, 4.1 ± 3.9 0 (0, 4)†, 2.3 ± 3.2 0.084
 OMERACT Power Doppler (median, IQR) (mean ± SD)† 2 (0.5, 5.5)†, 3.6 ± 4.1 0 (0, 3)†, 1.8 ± 2.7 0.030**
 Global OMERACT (median, IQR) 5 (3, 11) 1 (0, 5) 0.003**
HR-pQCT
 Erosion Number (median, IQR) 2 (0.5, 4.5) 2 (1, 4) 0.059
 Erosion Volume (median, IQR) 3.29 (0.40, 14.68) 3.87 (0.41, 16.7) 0.859
 Proliferation Grade (median, IQR) 2 (1,2) 2 (1.5, 2) 0.083
  1. HR-pQCT high-resolution peripheral quantitative computed tomography, IQR interquartile range, MRI magnetic resonance imaging, OMERACT outcome measures in rheumatoid arthritis clinical trials, PDUS power Doppler ultrasound, PSAMRIS psoriatic arthritis magnetic resonance imaging scoring system. †Additionally reported as mean and standard deviation (mean ± standard deviation) because median was equal to zero. Data are based on 17 psoriatic arthritis patients with complete baseline and 24 week data. Wilcoxon signed-rank test. *P ≤0.05, **P ≤0.01
Back to article page